title: Newer targeted therapies in psoriasis.
abstract: Psoriasis is a common, chronic, inflammatory skin disease that can have a significant impact on the quality of life of those who are afflicted due to chronicity of the disease and frequent remissions and relapses. Many available systemic therapies, however, are unsuitable for chronic administration due to the risk of cumulative toxicity. Recent advances in the understanding of the pathophysiology of psoriasis have led to the development of new, genetically engineered, targeted therapies for this disease. These include approaches targeting antigen presentation and co-stimulation, T-cell activation and leukocyte adhesion, action on pro-inflammatory mediators, and modulating the cytokine balance. Although only preliminary data are available so far and there is limited data supporting their use, these trials contribute to a further understanding of the disease and will eventually lead to new therapeutic options for psoriasis.
authors: Department of Dermatology and Venereology, AIIMS, New Delhi, India.
authors: Sujay
authors: S
authors: Khandpur
authors: Neetu
authors: N
authors: Bhari
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000938:Antigen-Presenting Cells / Q000276:immunology; D002117:Calcitriol / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D058990:Molecular Targeted Therapy; D011565:Psoriasis / Q000188:drug therapy*; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D019707:Receptors, Chemokine; D011993:Recombinant Fusion Proteins; D002117:Calcitriol